A detailed history of Goldman Sachs Group Inc transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 59,046 shares of ELYM stock, worth $242,679. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,046
Holding current value
$242,679
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.98 - $8.93 $294,049 - $527,280
59,046 New
59,046 $300,000
Q2 2022

May 14, 2024

BUY
$2.77 - $8.4 $450,933 - $1.37 Million
162,792 New
162,792 $492,000
Q2 2022

Aug 15, 2022

SELL
$2.77 - $8.4 $6,357 - $19,278
-2,295 Reduced 1.39%
162,792 $492,000
Q1 2022

May 16, 2022

BUY
$8.01 - $13.15 $7,721 - $12,676
964 Added 0.59%
165,087 $1.39 Million
Q4 2021

Feb 14, 2022

SELL
$8.61 - $20.47 $15,747 - $37,439
-1,829 Reduced 1.1%
164,123 $1.72 Million
Q3 2021

Nov 10, 2021

BUY
$14.45 - $28.61 $2.4 Million - $4.75 Million
165,952 New
165,952 $2.98 Million

Others Institutions Holding ELYM

About Eliem Therapeutics, Inc.


  • Ticker ELYM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,567,700
  • Market Cap $109M
  • Description
  • Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...
More about ELYM
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.